Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13915687 | 1.00 | KMT2A (0.63) | KMT2AMEN1ALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL3595931 | 0.85 | KMT2A (0.78) | KMT2AMEN1ALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL1886766 | 0.85 | KMT2A (0.78) | KMT2AMEN1ALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL15249477 | 0.85 | KMT2A (0.78) | KMT2AMEN1ALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL16250460 | 0.85 | KMT2A (0.78) | KMT2AMEN1ALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL3595934 | 0.85 | KMT2A (0.78) | KMT2AMEN1ALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL4274767 | 0.85 | L3MBTL1 (0.68) | KMT2AMEN1ALDH1A1CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL10854308 | 0.84 | KMT2A (0.76) | KMT2AMEN1ALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL3590498 | 0.83 | USP2 (0.65) | KMT2AMEN1ALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL7545873 | 0.82 | L3MBTL1 (0.65) | KMT2AMEN1ALDH1A1CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208984-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY | 2024-06-27 | — | — | US | disclosed |
| US-20240208984-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY | 2024-06-27 | — | — | US | disclosed |
| US-20240208984-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY | 2024-06-27 | — | — | US | disclosed |
| EP-4313051-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | Virginia Commonwealth University (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022212471-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2022-10-06 | — | — | WO | disclosed |
| US-10556899-B2 | Method for preparing Maraviroc | SCI PHARMTECH, INC. (TW) | 2020-02-11 | — | — | US | disclosed |
| US-20190248782-A1 | METHOD FOR PREPARING MARAVIROC | SCI PHARMTECH, INC. (TW) | 2019-08-15 | — | — | US | disclosed |
| WO-2014173375-A1 | A PROCESS FOR THE SYNTHESIS OF MARAVIROC | ZENTIVA, K.S. (CZ) | 2014-10-30 | — | — | WO | disclosed |
| CN-102766141-B | Preparation method of 8-benzyl-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo (3.2.1)octane | WENZHOU MEDICAL COLLEGE | 2014-09-03 | — | — | CN | disclosed |
| US-8779143-B2 | Crystalline forms of maraviroc phosphate and process for maraviroc amorphous form | HETERO RESEARCH FOUNDATION (IN) | 2014-07-15 | — | — | US | disclosed |
| US-20070015788-A1 | N-(3-Aryl-3-substitutedphenylpropyl) piperidines or 8-azabicyclo[3.2.1]octanes that are additionally substituted with an optionally fused 5-member N-heterocycle; the compounds are modulators of CCR5 receptor activity and are used in treating diseases such as rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | disclosed |
| US-20070015788-A1 | N-(3-Aryl-3-substitutedphenylpropyl) piperidines or 8-azabicyclo[3.2.1]octanes that are additionally substituted with an optionally fused 5-member N-heterocycle; the compounds are modulators of CCR5 receptor activity and are used in treating diseases such as rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | disclosed |
| US-20070015788-A1 | N-(3-Aryl-3-substitutedphenylpropyl) piperidines or 8-azabicyclo[3.2.1]octanes that are additionally substituted with an optionally fused 5-member N-heterocycle; the compounds are modulators of CCR5 receptor activity and are used in treating diseases such as rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | US | disclosed |
| EP-1742934-A2 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | AstraZeneca AB (SE) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005101989-A2 | PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | WO | disclosed |
| EP-1526134-A2 | TRIAZOLYL TROPANE DERIVATIVES AS CCR5 MODULATORS | Pfizer Limited (GB) | 2005-04-27 | — | — | EP | disclosed |
| US-20040067977-A1 | Tropane derivatives useful in therapy | PFIZER, INC. | 2004-04-08 | — | — | US | disclosed |
| EP-1284974-B1 | TRIAZOLYL TROPANE DERIVATIVES AS CCR5 MODULATORS | PFIZER LTD (GB) | 2004-03-03 | — | — | EP | disclosed |
| US-6667314-B2 | For therapy of respiratory disorder including adult respiratory distress syndrome (ARDS), bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, asthma, emphysema, rhinitis or chronic sinusitis | PFIZER, INC. | 2003-12-23 | — | — | US | disclosed |
| US-20020013337-A1 | Tropane derivatives useful in therapy | PHIVCO-1 LLC | 2002-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015788-A1 | N-(3-Aryl-3-substitutedphenylpropyl) piperidines or 8-azabicyclo[3.2.1]octanes that are additionally substituted with an optionally fused 5-member N-heterocycle; the compounds are modulators of CCR5 receptor activity and are used in treating diseases such as rheumatoid arthritis | CCR5, CCR2, CX3CR1 | KMT2A 4078/4885MEN1 4834/4885ALDH1A1 531/4885 |
| US-20020013337-A1 | Tropane derivatives useful in therapy | ADRB3, ADRA1A, ADRB2 | KMT2A 4068/4885MEN1 2363/4885ALDH1A1 454/4885 |
| US-20040067977-A1 | Tropane derivatives useful in therapy | ADRB3, ADRA1A, ADRB2 | KMT2A 4068/4885MEN1 2363/4885ALDH1A1 454/4885 |
| US-10556899-B2 | Method for preparing Maraviroc | CYP3A43, NAT10, CYP3A5 | KMT2A 1506/4885MEN1 4007/4885ALDH1A1 663/4885 |
| US-20240208984-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | OPRM1, OPRK1, CCR5 | KMT2A 3025/4885MEN1 4850/4885ALDH1A1 3596/4885 |
| US-20190248782-A1 | METHOD FOR PREPARING MARAVIROC | CYP3A43, NAT10, CYP3A5 | KMT2A 1506/4885MEN1 4007/4885ALDH1A1 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.